Drug intelligence / Profile preview

MGE-201

Development stage: Unknown
Lead developer: Primera Therapeutics
Modality: Gene Therapies
Administration: Intravenous

Overview

MGE-201 is an investigational systemic in vivo mitochondrial gene editing therapy being developed by Primera Therapeutics. It is designed to address mitochondrially driven disorders by utilizing a gene editing platform to correct or modify mutations within the mitochondrial DNA (mtDNA). The therapy is intended for systemic administration to reach multiple tissues affected by mitochondrial dysfunction. According to company pipeline information, MGE-201 has entered Phase 1 clinical development for unspecified mitochondrial disorders.

Targets

mtDNA (Mitochondrial DNA)

Beyond the preview

Go deeper on MGE-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGE-201.

Explore the full profile